找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Optimal Use of Sandimmun in Endogenous Uveitis; D. BenEzra,R. B. Nussenblatt,P. Timonen Conference proceedings 1988Latest edition Sandoz L

[復(fù)制鏈接]
樓主: ARSON
11#
發(fā)表于 2025-3-23 10:45:35 | 只看該作者
12#
發(fā)表于 2025-3-23 14:16:02 | 只看該作者
results achieved so far with conventional therapy using systemic corticosteroids and cytotoxic agents, new treatment modalities have been sought. a) Start treatment with Sandimmun at initial doses of During the last four years, a total of over 300 patients 5 mg/kg/day. b) Use Sandimmun in combinatio
13#
發(fā)表于 2025-3-23 21:00:13 | 只看該作者
14#
發(fā)表于 2025-3-23 23:42:02 | 只看該作者
Present Experience with Sandimmun,ine, (97 patients) or placebo (12 patients). Most patients receiving Sandimmun had an initial loading dose of 5 to 10 mg/kg/day followed by a dose reduction according to ocular inflammatory activity and tolerability.
15#
發(fā)表于 2025-3-24 04:39:22 | 只看該作者
Introduction: Endogenous Uveitis, to the iris (iritis), the ciliary body (cyclitis) or both (iridocyclitis), the manifestation is coined anterior uveitis. Localization of the inflammatory reaction to the pars plana and peripheral fundus (pars planitis) as well as vitreous (vitritis) is coined intermediate uveitis, while posterior u
16#
發(fā)表于 2025-3-24 06:38:41 | 只看該作者
Conference proceedings 1988Latest editionndent studies all over the d) Taper Sandimmun dose as rapidly as possible to a world (over 200 patients) and in a masked manner in 4 maintenance dose below 5 mg/kg/day. e) Do not discontinue treatment with Sandimmun rap- independent controlled studies (over 100 patients re- idly.
17#
發(fā)表于 2025-3-24 12:24:38 | 只看該作者
18#
發(fā)表于 2025-3-24 15:51:40 | 只看該作者
19#
發(fā)表于 2025-3-24 20:32:39 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
20#
發(fā)表于 2025-3-25 00:38:40 | 只看該作者
D. BenEzra M.D., Ph.D.,R. B. Nussenblatt M.D.,P. Timonen M.B.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 14:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
楚雄市| 台州市| 西畴县| 锦州市| 湾仔区| 承德市| 察雅县| 离岛区| 陵川县| 穆棱市| 荥阳市| 延长县| 万州区| 韶山市| 清丰县| 蒲江县| 明溪县| 邢台县| 大邑县| 观塘区| 滦南县| 彭水| 绿春县| 榆树市| 新竹市| 易门县| 神农架林区| 武邑县| 扶风县| 义马市| 忻城县| 开鲁县| 萝北县| 南岸区| 电白县| 卢龙县| 中阳县| 武安市| 探索| 广州市| 大同县|